Abstract. Oral cancer (OC) is a largely asymptomatic disease, resulting in one of the highest mortality rates of any cancer. OC is currently ranked as the sixth most common cancer in the world, according to a recent World Health Organization analysis, and its prevalence is increasing, both in western and developing regions. Depending on the stage of OC, treatment strategies include surgery, radiation therapy and chemotherapy, or a combination thereof. As with numerous other types of cancer, resistance to conventional chemotherapeutic drugs is increasing in oral squamous cell carcinoma (OSCC). The present study aimed to investigate the use of a novel group of compounds, the pyrrolo-1,5-benzoxazepines (PBOXs), as a therapeutic alternative for the treatment of OC. PBOXs are microtubule-targeting agents that are able to induce apoptosis in numerous cancer cell types, thereby preventing tumour cell proliferation. Ca9.22 gingival and TR146 buccal cell lines were used as models for OSSC. Cell viability and proliferation in the presence of two PBOXs: PBOX-6 and PBOX-15, was monitored using an AlamarBlue TM assay. Flow cytometric analysis of propidium iodide-stained cells was used to determine the DNA content, and therefore the percentage of cells in each phase of the cell cycle. Microtubule disruption was determined by indirect immunofluorescence staining. Changes in protein expression and degradation were determined by western blotting. The results of the present study indicated that both PBOX-6 and -15 were able to induce apoptotic cell death by disrupting the microtubule network in both cell lines. The EC 50 values were subsequently calculated for both PBOX-6 and -15, and PBOX-15 was shown to possess a higher potency. Both compounds displayed anti-proliferative effects mediated through sustained G 2 /M arrest accompanied by tubulin disruption, and a decrease in DNA repair protein poly (ADP ribose) polymerase expression. These findings suggest that PBOXs may prove useful, either alone or in combination with other agents, in the treatment of chemotherapeutic resistant OSCC.
Introduction
Oral cancer (OC) is the sixth most common cancer worldwide and has one of the highest mortality rates, due to it being largely asymptomatic until the latter stages of the disease. Cancers of the oral cavity include cancers that occur in the tongue, floor of the mouth, buccal mucosa, alveolus, retromolar trigone, gingival, hard palate, and lips (1, 2) . A total of 90% of OCs are squamous cell carcinomas (SCC) (3) . SCC is caused by the presence of malignant cells in the epithelium. Oral SCC (OSCC) accounts for 2-3% of all malignancies, the prevalence of which ranges between 1-10 cases per 100,000 people in the majority of countries (4) .
OSCC prognosis is poor, with a 5-year survival rate of ~50%, according to the National Cancer Research Institute (5). Treatments for OSCC are usually limited to a combination of chemotherapy and radiation, in order to reduce tumour size prior to the surgical removal of the tumour margins. Two of the most common chemotherapeutic agents used in the treatment of OSCC are cisplatin and 5-fluorouracil (6) , and recurrent tumours are usually treated with one of these two chemotherapy drugs. However, resistance to these drugs may develop following treatment, as is the case in numerous types of cancer (7, 8) .
Pyrrolo-1,5-benzoxazepines (PBOXs) are a novel family of compounds that have been shown to induce cell cycle arrest and apoptosis in numerous cancer cell lines, including chemotherapy-resistant cell lines (9, 10) . In addition, PBOXs have been shown to induce cell apoptosis in ex vivo patient samples and in in vivo animal models of breast cancer and chronic myeloid leukaemia (10, 11) . Notably, PBOXs display minimal toxicity towards normal blood and bone marrow cells (12) . A recently improved understanding regarding the molecular mechanisms underlying the apoptotic effects of PBOX compounds has allowed their development as antineoplastic therapeutic agents. Within the PBOX family, two (13) previously demonstrated that PBOX-induced apoptosis in cancer cells is preceded by a marked G 2 /M phase cell cycle arrest, and that the cells displayed morphological features that suggested an inhibition of mitosis, notably in pro-metaphase. The effects of PBOXs on cell morphology are similar to those induced by two microtubule-targeting drugs, paclitaxel and nocodazole, which are polymerising and depolymerising agents, respectively. These results are concordant with previous studies that also demonstrated that anti-microtubule agents arrest the cell cycle in pro-metaphase (14, 15) .
Previous studies have suggested that PBOXs possess anti-microtubule activity. Through indirect immunofluorescence analysis, Mulligan et al (13) demonstrated that pro-apoptotic PBOX compounds result in depolymerisation of the microtubule network, and an inhibition of the assembly of purified tubulin in vitro. Tubulin has therefore been identified as the molecular target of the pro-apoptotic PBOX compounds (15) .
In the present study the pro-apoptotic capabilities of two representative members of the PBOX family, PBOX-6 and PBOX-15, were examined in the TR146 (buccal mucosa) and Ca9.22 (gingival carcinoma) cell lines. The aim of the present study was to investigate the potential of these compounds on inhibiting the proliferation of OSCC cells. The present study also examined the cell death mechanism and efficacy of the compounds and aimed to determine the effectiveness of the compounds against OSCC cells with differing genotypes. Together, the results from the present study may indicate the potential of the PBOX compounds in the treatment of OSCC, and whether there is in merit further investigation, either alone, or in combination with other agents as a potential treatment modality for OC. , were synthesized as previously described (16) . The PBOX compounds were subsequently dissolved in 1% ethanol, and stored at -20˚C. The antibodies used in the present study were as follows: Mouse anti-human/rat/mouse anti-α-tubulin (cat. no. CP06; EMD Millipore, Billerica, MA, USA); mouse anti-human anti-poly (ADP ribose) polymerase (PARP; cat. no. MABC547; Merck Biosciences Ltd., Nottingham, UK); and mouse anti-β-actin (cat. no MAB1501; EMD Millipore).
Materials and methods

Reagents
Cell culture. Both cell lines were maintained in a 95% humidified atmosphere containing 5% CO 2 at 37˚C, and all cell culture experiments were carried out under sterile conditions in a laminar flow hood. Cell growth and viability were visually monitored using a light microscope (Nikon Eclipse TS100; MicronOptical, Wexford, Ireland) with 10 and 20x dry objectives. The TR146 cell line was initially derived from the neck node of a 67 year-old female (the primary tumour was located in the buccal mucosa) and was obtained from the Health Protection Agency Culture Collection (Salisbury, UK). The TR146 cells were maintained in Dulbecco's Modified Eagle's medium, supplemented with 10% v/v foetal bovine serum (FBS), 10 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM glutamine. The Ca9.22 cell line was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). The Ca9.22 cells were maintained in Minimum Essential medium, supplemented with 10% v/v FBS, 10 U penicillin, 0.1 mg/ml streptomycin, and 2 mM glutamine. All control cells were treated with vehicle (1% ethanol) alone.
Cell proliferation. Cell proliferation was determined using AlamarBlue TM dye (Life Technologies, Grand Island, NY, USA), which allowed the visualisation of changes in compound fluorescence that occur as a consequence of the reduced number of viable, proliferating cells. The cells were seeded in 96-well plates for each of the time points with specified concentrations of PBOX-6 (10 nM-100 µM) or PBOX-15 (1 nM-250 µM), and were incubated at 37˚C in 5% CO 2 . A final concentration of 10% (v/v) AlamarBlue TM was added to the cells 4 h prior to the end of each time point. Fluorescence was measured at an excitation wavelength of 544 nm and at an emission wavelength of 590 nm, using a SpectraMax Gemini spectrofluorometric plate reader (Molecular Devices (UK) Ltd, Wokingham, UK). Cell viability was determined as a percentage of the vehicle-only cells. The experimental results were displayed as dose-response curves and half maximal effective concentration (EC 50 ) values, as determined using Prism GraphPad 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Immunofluorescence. The cells were cultured for 24 h on 13 mm glass coverslips with the following seed densities: Ca9.22, 3x10 4 cells/coverslip; and TR146, 4x10 4 cells/coverslip. The cells were subsequently cultured in the presence of either PBOX-6 or PBOX-15 for a further 24 h. Following incubation, the cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min, permeabilised with 0.2% Triton in PBS for 10 min, rinsed with PBS, and blocked using 1% bovine serum albumin (BSA) in PBS containing Tween ® 20 (PBST) for 30 min. The cells were then incubated with the following primary antibodies: Mouse anti-α-tubulin (1:1,000) in 1% BSA and PBST for 1 h, prior to incubation with secondary goat anti-mouse antibody 488 (cat. no. a-11001; Life Technologies; 1:500) in 1% BSA and PBST for 1 h. The coverslips were then placed on glass slides with 3.5 µl Vectashield TM mounting medium (Vector Labs, Burlingame, CA, USA) containing the nuclear counterstain 4,6-diamidino-2-phenylindole (DAPI), and stored in the dark at 4˚C until imaging. The indirect fluorescence of the cells was examined using a standard filter set for DAPI and blue/green, through 10 and 20x dry objectives, and a 60x oil objective using a Zeiss Axiovert/Axiocam CCD system, and imaged using AxioVision AxioVs40 software (Carl Zeiss Ltd., Cambridge, UK).
DNA content. The cellular DNA content was determined using of propidium iodide (PI), an intercalating fluorescent dye. The fluorescence intensity is proportional to the quantity of DNA present in the cell. Both cell lines were cultured in the presence of PBOX-6 or PBOX-15 at the desired concentrations and time points. The cells were then harvested by trypsinisation, prior to being centrifuged at 220 x g for 5 min, washed with PBS, and centrifuged once more. The supernatant was decanted and the cell pellets were resuspended in 200 µl PBS, prior to the addition of 2 ml ice-cold 70% ethanol in order to fix the cells. Following overnight fixation at 4˚C, the cells were centrifuged at 200 x g for 5 min in order to remove the ethanol, and the pellet was resuspended in 400 µl PBS, followed by 25 µl RNase A, and 75 µl PI. The cells were incubated in the dark at 37˚C for 30 min. The samples were subsequently transferred to appropriately labeled fluorescence activated cell sorting (FACS) tubes, and were analysed using a FACSCalibur flow cytometer (BD Biosciences, Oxford, UK). The fluorescent signal was detected using a 630-22 nm band pass filter (FL2). The cell lines were gated in order to prevent cell debris and doublets from being counted. A total of >10,000 cells were counted and analysed using Treestar FlowJo v10 (FlowJo, Oregon, OR, USA).
Analysis of protein expression by western blotting.
The cells cultured in the presence of PBOX-6 or PBOX-15 for 24, 48, and 72 h, were harvested and centrifuged at 220 x g for 5 min, following which the supernatants were discarded and the cell pellets were resuspended in 2 ml ice-cold PBS. Following further centrifugation at 220 x g for 5 min, the supernatant was removed and the pellets were resuspended in 80 µl ice-cold lysis buffer (150 mM sodium chloride, 1.0% Triton X-100, 50 mM Tris; pH 8.0) containing Complete Protease Inhibitor Cocktail (Roche Diagnostics Ltd., Burgess Hill, UK). The samples were maintained under constant agitation at 1,000 rpm for 30 min at 4˚C, prior to being centrifuged at 13,000 x g for 20 min at 4˚C. The supernatants were aspirated and placed in an eppendorf tube on ice until further experimentation. The protein concentrations were deterxwmined using a bicinchoninic acid assay. The protein samples were separated by SDS-PAGE with an 8% resolving gel. The proteins were then transferred to a polyvinylidene difluoride (PVDF) membrane using a semi-dry blotter for 1 h. The PVDF membranes were subsequently blocked with 5% non-fat milk, and probed with the appropriate primary antibodies prior to being incubated with horseradish peroxidase-conjugated goat anti-mouse secondary antibody (cat. no. sc2031; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Protein expression was visualised through chemiluminescence using an Immobilon Western Chemiluminescent HRP substrate (Merck Millipore, Darmstadt, Germany).
Statistical analysis. Statistical significance was determined using Prism GraphPad 5 (GraphPad Software, La Jolla, CA, USA). Analysis was performed using an unpaired t-test with post-hoc Bonferroni analysis. P<0.001 was considered to indicate a statistically significant difference.
Results
PBOX compounds reduce OC cell proliferation. The OSCC cell lines were treated for 72 h with PBOX-6 or PBOX-15 at various concentrations. Cell proliferation was subsequently measured using AlamarBlue TM assay. The results of the assay indicated that PBOX-6 and PBOX-15 reduced proliferation of both the Ca.922 and the TR146 cell lines in a dose-dependent manner (Fig. 2) . PBOX-15 was the more potent of the two analogues. After 72 h, the EC 50 values of PBOX-6 and PBOX-15 were 35±2.7 µM and 470±86 nM for the TR146 cells, and 2.6±1 µM and 83±32 nM for the Ca9.22 cells, respectively (Table I ). The drug concentrations used for the remaining experiments were chosen according to the results of this cell proliferation assay.
PBOX compounds destabilise and depolymerise the microtubule network in OC cells. The Ca9.22 and TR146 cells were treated with either PBOX-6 or PBOX-15 for 24 h. In addition, the cells were also treated with the known tubulin polymeriser, paclitaxel (1 µmol; 24 h), and the tubulin depolymeriser, nocodazole (10 µmol; 24 h), both purchased from Sigma-Aldrich, which served as positive controls. Immunofluorescent staining was used to detect morphological changes in the microtubule network, such as alterations in microtubule organisation and arrangement ( Fig. 3) . In the vehicle TR146 (Fig. 3A) and Ca9.22 (Fig. 3B ) cells, the microtubule network was organised as cytoplasmic tubulin filaments radiating from a central point to the periphery. Exposure of the cells to the tubulin polymerising agent paclitaxel resulted in a highly concentrated accumulation of filaments in dense peripheral bundles, indicative of microtubule stabilisation. Conversely, exposure to the tubulin depolymerising agent nocodazole resulted in diffuse tubule staining with no definition of structure caused by microtubule disassembly. No alterations in microtubule structure were evident following treatment with a low dose of 100 nM PBOX-6 and PBOX-15, whereas higher doses of 10 µM PBOX-6 and 1 µM PBOX-15 resulted in a change in tubulin morphology resembling that induced by nocodazole. These results indicate that PBOX compounds destabilise the microtubule network in a similar manner to a depolymerising agent, in both TR146 and Ca9.22 cell lines.
In order to confirm the results of previous studies, namely that the disruption observed using a confocal microscope is the result of depolymerisation of the tubulin network, tubulin polymerisation assays were performed using western blotting (Fig. 3C) . Following 4 h treatment with 10 µM PBOX-6 or 1 µM PBOX-15, tubulin was shown to be completely depolymerised in both cell lines. Following 4 h treatment with paclitaxel, tubulin was polymerised, whereas treatment with nocozadole resulted in unpolymerised tubulin. Treatment with the vehicle (1% EtOH) resulted in equal amounts of polymerised to unpolymerised tubulin. These results indicate that the disruption observed by confocal microscopy was indeed depolymerisation of the tubulin network. Fig. 4C and 4D ).
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PBOX compounds induce degradation of PARP in OC cell
lines. In order to confirm that the cell death observed during flow cytometric analysis was indeed cellular apoptosis, PARP degradation, which is associated with controlled cell death, was assessed. Concordant with the DNA content analysis results, both PBOX-6 (10 µM) and PBOX-15 (1 µM) induced a decrease in the expression levels of full length PARP in Ca9.22 and TR146 cells following 72 h treatment ( Fig. 4E and 4F) . Treatment with the vehicle (1% (v/v) EtOH) did not affect PARP expression in either cell line. In the TR146 cell line, PARP degradation was observed following 24 h treatment with 1 µM PBOX-15, as compared with the vehicle control. PARP degradation was clearly observed in the TR146 cell line following 48 h treatment with both PBOX compounds. In addition, PARP degradation was also observed in the Ca9.22 cell line following 48 h treatment with both PBOX compounds. β-actin was used as a loading control in all experiments. These results indicate that the PBOX compounds induce apoptosis via tubulin disassembly.
Discussion
The present study assessed a novel set of compounds with regards to their potential therapeutic value in OC. PBOX-15 and PBOX-6 are potent pro-apoptotic members of the PBOX family, and have previously been shown to induce apoptosis The polymerised (P) or unpolymerised (U) tubulin was then separated by centrifugation in a microtubule-preserving buffer. The ratio of polymerised, vs. unpolymerised tubulin was subsequently assessed by western blot analysis using monoclonal antibodies directed against tubulin and loading control β-actin, followed by incubation with horseradish peroxidase-conjugated anti-mouse antibody. The images are representative of experiments repeated three times.
in numerous human tumour cell lines, and to have anti-cancer properties in various cell culture systems, animal models, and clinical samples (11, 17) . In addition to inducing apoptosis in various cancer cell types, PBOX-6 and -15 possess the added benefit of inducing cytotoxicity in multi drug-resistant cancer cells (18) . The present study demonstrated that PBOX compounds were capable of reducing the proliferation of OC cell lines TR146 and Ca9.22, with EC 50 values of 35±2.7 µM and 2.6±1 µM for PBOX-6, and 470±86 nM and 83±32 nM for PBOX-15. These values are within a range previously observed in other cancer cell lines exposed to PBOX compounds, including K562 chronic myeloid leukemia cells, A2780 ovarian carcinoma cells, and various cancerous mammary cells (9, 16, 17) . PBOX-15, as previously reported, is the more potent of the two compounds, a result that was confirmed in the present study in both cell lines tested, as demonstrated by the order of magnitude of difference in the calculated EC 50 values. Significant variation in the sensitivity of each cell type to PBOX treatment was also observed. The Ca9.22 gingiva cell line was sensitive to both PBOX-15 and PBOX-6, and had significantly lower EC 50 values, as compared with the TR146 buccal cell line. The observed variation in efficacy of the PBOXs in the two experimental cell lines suggests a phenotypic or genotypic factor may be involved. In OSCC, ~50% of cases are associated with a mutation in the p53 gene, which results in deleterious phenotypic manifestations and impaired p53 function. The Ca9.22 cells have a known p53 mutation (19) , whereas the TR146 cells have no known p53 mutation. Previous studies have reported the influence of p53 in modifying drug efficacy and function in cancer cells (20, 21) .
The disassembly of the microtubule network in other cancer cell lines following treatment with PBOX-6 and PBOX-15 suggested that the compounds act as microtubule depolymerizing agents (13) . To examine this hypothesis in OSCC, the Ca9.22 and TR146 cells were treated with various concentrations of PBOX-6 and PBOX-15. The results of the present study were concordant with previous studies, demonstrating that both PBOX compounds caused disassembly of tubulin following 24 h treatment in vitro (13, 22) . In the case of the control compounds, nocodazole depolymerised tubulin, whereas treatment with paclitaxel resulted in tubulin aggregation through polymerisation. PBOX-15, the more potent of the two compounds, was effective at disrupting tubulin at 1 µM in both cell lines, whereas PBOX-6-mediated depolymerisation was only observed at concentrations of 10 µM.
This inhibition of tubulin assembly is likely to be the cause of cell death following treatment with the PBOX compounds (13) . Tubulin is a key protein in spindle formation during the cell cycle. A mechanism known as the spindle 
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assembly checkpoint is activated during metaphase in the cell cycle (23) . In the presence of tubulin breakdown and loss of spindle tension, the cell will not be able to continue into anaphase. In order to determine part of the mechanism underlying the response of OSCC cells to PBOX treatment, the effects of PBOX-6 and PBOX-15 on the cell cycle were examined. The PBOXs caused a time-dependent accumulation of cells in G 2 /M phase, as early as 4 h in TR146 cells, and 8 h in Ca9.22 cells. This was followed by an increase in the number of cells in sub-G 0 /G 1 phase, indicative of apoptosis and a concomitant decrease in the percentage of cells in G 2 /M. To confirm the mechanism of cell death, degradation of the DNA repair enzyme PARP, which is indicative of apoptosis, was examined. A decrease in the expression levels of the full-length 116 kDa PARP was evident in both cell lines following treatment with both compounds after 72 h, suggesting PARP had been cleaved. The decrease in full-length PARP in the Ca9.22 cell line was more prominent than in the TR146 cell line, demonstrating an increased sensitivity of the Ca9.22 cells to the compounds as it also increased the EC 50 values obtained using this cell line.
The results of the present study indicated that PBOX-6, and its more potent analogue PBOX-15, may prove effective in the treatment of OSCC. The present study has shown that PBOX-6 and PBOX-15 depolymerise their molecular target, tubulin, resulting in cell death through apoptosis in OSCC cell lines. Given the prevalence of OSCC, the use of PBOX compounds as topical agents may be a potential therapeutic strategy for this disease. PBOX compounds used alone or in combination with other antineoplastic agents may prove useful in the treatment of OSCC.
